This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Epson petitions USITC to investigate Chinese printer ink manufacturers

By Nick Robertson ( May 15, 2025, 14:51 GMT | Insight) -- Seiko Epson Corp. on Tuesday petitioned the US International Trade Commission to investigate 19 Chinese companies over potential violations of Section 337 of the Tariff Act, alleging that the firms infringed 10 Epson patents for printer ink cartridges. The two petitions seek an exclusion order barring the importation of the allegedly infringing ink cartridges and components.A group of Chinese companies are importing printer ink cartridges and components into the US which infringe 10 Seiko Epson Corp. patents, Epson alleged in two US International Trade Commission petitions received on Tuesday. The petitions allege violations of Section 337 of the Tariff Act, seeking an exclusion order to bar the 19 Chinese firms from importing the allegedly infringing products into the US, in addition to a cease and desist order....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections